By Brazil Stock Guide – Biomm S.A. (B3: BIOM3) signed an initial R$131 million contract under a 10-year partnership with China’s Gan & Lee Pharmaceuticals and Brazil’s Bio-Manguinhos/Fiocruz to supply Insulin Glargine to the national health system. The deal, disclosed through the government’s National Public Procurement Portal (PNCP), covers the first deliveries scheduled for 2025 and partially fulfills the first year of the broader supply contract.
The partnership — a Parceria para o Desenvolvimento Produtivo (PDP) — is part of Brazil’s strategy to strengthen its domestic pharmaceutical industry under the Ministry of Health’s SECTICS Ordinance No. 59 of November 2024. The initiative seeks to cut dependence on imported insulin while fostering local manufacturing and technological capacity.
According to Biomm, the program could speed up the replacement of human insulin by glargine formulations, already the world’s most widely used basal insulin. The company expects to capture 30% of Brazil’s market within the first year of deliveries and eventually reach up to 85%, mirroring global usage patterns.
“This agreement is a landmark for both Biomm and Brazil’s national health system,” said CFO and Investor Relations Officer Marcelo Safádi Alvares, noting that the project aligns commercial returns with public health priorities. The company said it will keep investors informed as implementation advances.